Head to Head Survey: Alpha Cognition (NASDAQ:ACOG) and Tenaya Therapeutics (NASDAQ:TNYA)

Tenaya Therapeutics (NASDAQ:TNYA) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Valuation & Earnings

This table compares Tenaya Therapeutics and Alpha Cognition”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$124.08 million	($1.16)	-0.61
Alpha Cognition	$2.93 million	51.31	-$13.77 million	($1.20)	-7.82

Alpha Cognition has higher revenue and earnings than Tenaya Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tenaya Therapeutics has a beta of 2.91, indicating that its share price is 191% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Tenaya Therapeutics and Alpha Cognition, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	0	0	7	0	3.00
Alpha Cognition	0	0	1	0	3.00

Tenaya Therapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 786.52%. Alpha Cognition has a consensus target price of $20.00, suggesting a potential upside of 113.22%. Given Tenaya Therapeutics’ higher possible upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than Alpha Cognition.

Insider and Institutional Ownership

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 48.7% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 14.0% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Tenaya Therapeutics and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-86.17%	-71.14%
Alpha Cognition	N/A	N/A	-344.17%

Summary

Tenaya Therapeutics beats Alpha Cognition on 8 of the 11 factors compared between the two stocks.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.